PerfIL-17 Study: IL-17 Inhibitor Patterns, Persistence Among Patients with PsA
The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.
Stay updated with breaking news from World Persistence. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation...
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium...
AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.
The Law mod is available to download now on NexusMods